Skip to content

anicells

Active
Private limited company (pre-2019)founded 20197 yrs activeGalileilaan 21, 2845 Niel, BelgiumKBO/BCE: BE 0725.459.634
Summary

anicells has been active since 2019 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €105,520 and a net result of €53,313. Equity is growing by ~81.2% per year across the filed fiscal years. Its solvency ranks better than 17% of 563 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).

Risk analysisWatch ReportCompare
anicellsActiveChecked score 90/100
Risk analysis ReportCompare

Overview

Activity
Research and development on biotechnology
NACE 72101Manufacture of basic pharmaceutical products and pharmaceutical preparations NACE 21209NACE 72110
1 site
Size
€1.8mtotal assets 2025
Staff
11 FTE
Equity
€105,520
Profit
€53,313
Turnover not published (abridged schema)
Financial health
90 Excellent Checked score 2025
Bankruptcy chance 12 m
0.2%
Structure
Accounts 17 d early0 of 1 deed read
Why 90- Equity €105,520 (5.8% of total assets)+ Sector Scientific research and development (NACE 72)+ Size: total assets €1.8m+ Liquidity: current ratio 1.18, cash €454,038Show the evidence

Checked score

Score 2025
90 / 100
Excellent
Probability in this band: under 0.55%
Better than 54% of its sector peers (NACE 72, micro)
Performance against the sector, not lower risk
Every signal that weighs is under Signals.
Financial strength · tick = 2024
Average
Solvency 31+2
equity 5.8% of total assets
Liquidity 65-9
short-term debt 36.5% · cash 25.1%
Profitability 72+1
return on assets 2.9%
Bankruptcy probability, 12 months
0.2% Very low
0%0.5%1.5%4%10%≥ 25%

About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.2% (925 companies)
Last 18 months 05-2025: 0.1%lowest value 06-2025: 0.1%▲ +10.5% vs 05-2025 07-2025: 0.1%▲ +6.3% vs 06-2025 08-2025: 0.1%▲ +8.9% vs 07-2025 09-2025: 0.1%▲ +17.3% vs 08-2025 10-2025: 0.2%▲ +22.5% vs 09-2025 11-2025: 0.1%▼ -44.3% vs 10-2025 12-2025: 0.1%▲ +1.1% vs 11-2025 01-2026: 0.1%▲ +1.1% vs 12-2025 02-2026: 0.1%● 0.0% vs 01-2026 03-2026: 0.1%▲ +1.1% vs 02-2026 04-2026: 0.1%▼ -1.1% vs 03-2026 05-2026: 0.1%▲ +4.4% vs 04-2026 06-2026: 0.1%▲ +4.3% vs 05-2026 07-2026: 0.1%▲ +5.1% vs 06-2026 08-2026: 0.1%▲ +15.5% vs 07-2026 09-2026: 0.1%▲ +19.3% vs 08-2026 10-2026: 0.2%▲ +25.4% vs 09-2026highest value
  • Sector Scientific research and development (NACE 72) lowers the probability
  • Size: total assets €1.8m lowers the probability for this profile
  • Equity €105,520 (5.8% of total assets) raises the probability
  • Liquidity: current ratio 1.18, cash €454,038 lowers the probability
Credit up to €9,000 at 30 days acceptable
Liquidity tight (current ratio 1.18 against 1.24 in 2024; short-term debt: 36.5% and cash: 25.1% of total assets), and 94.2% of the assets are financed with debt.
How it is calculated

The band comes from the bankruptcy probability on a scale of 0 to 100: every 10 points more double the odds of getting through the year without bankruptcy.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Place inside the band: half the bankruptcy probability, half how the company does against its sector peers (NACE 72, micro). Better than this share of them on solvency 21%, liquidity 54%, profitability 47%, growth against the median 92%. That is performance, not lower risk; the band itself always comes from the probability.

Bankruptcy probability: model pd-v3.202610021621, computed on 02-10-2026. The model learns from Belgian bankruptcies and reads the registers, the annual accounts and the gazette.

Ceilings: negative or zero equity, a heavy loss, a special KBO legal situation and a missing filing 59 (two missing 44), an ongoing judicial reorganisation or an ending 24. Financial strength does not count in the score.

Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Sector Scientific research and development (NACE 72)
In the bankruptcy model this factor lowers the probability.
KBO
lowers risk · Size: total assets €1.8m
In the bankruptcy model this factor lowers the probability for this profile.
NBB · annual accounts
raises risk · Equity €105,520 (5.8% of total assets)
In the bankruptcy model this factor raises the probability.
NBB · annual accounts
lowers risk · Liquidity: current ratio 1.18, cash €454,038
In the bankruptcy model this factor lowers the probability.
NBB · annual accounts
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 17% of 563 sector peers (2025).
NBB · sector comparison
Position among 563 sector peers
Solvency
better than 17%
← weakest strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-03-2025 was due by 31-10-2025 and was filed on 14-10-2025, 17 days ahead of the deadline.
NBB · 6 filings
Deviation from the deadline
2025
17 d early
2024
22 d early
2023
33 d early
2022
3 d late
2021
31 d early
2020
30 d late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 6 accounts on average 12 days before the deadline; the sector median for financial year 2024 is 13 days before the deadline, and 32% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-03-2026 and is due by 31-10-2026. Nothing is late today. Usually files around 9 October (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Position in the running window
31-03-2026 close02-10-2026 today31-10-2026 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage
  1. Annual accounts filedfiscal year 2025 · micro…
  2. Equity above €100,000Eq €105,520 ▲102%
  3. Annual accounts filedfiscal year 2024 · micro…

Key points

  • Positive: Staff rose in 2025from 5.1 FTE to 11 FTE ▲ 116% View
  • Caution: Among the weakest 18% on solvencysector median 61.4% · 563 companies 5.8% View
  • Flemish supportawarded 2024 - 2025 €399,910 View
  • Positive: 5 profitable years in a rowprofit 2025: €53,313 5 years View

By topic

Financials

Fiscal year
2025
Total assets
€1.8m
Profit
€53,313
Solvency
5.8%
Total assets▲ 25.0%
Net result
20202025
Go to Financials

Timeline

Events
9
Since
2020
Next accounts
by 31-10-2026
  1. 14-10-2025Annual accounts filed
  2. 31-03-2025Equity above €100,000
  3. 09-10-2024Annual accounts filed
Go to Timeline

Company details

Sites
1
Legal form
Private limited company (pre-2019)
Activity
Research and development on biotechnologyNACE 72101
Founded
17-04-2019
Year ends
31-03
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What other support did companies like this one receive, and it did not?Subsidies How does this company compare with its sector?Sector benchmark

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure